Vinita Gupta_The architect of Lupin's success

Today's DNA Reports the success story of Lupin and the role of Vinita Gupta has played in this journey. 

Excerpts: 
The $880 million (Rs 5,610 crore) takeover of the US-based Gavis Pharmaceuticals by Lupin, the biggest-ever overseas acquisition by an Indian pharma company, has brought to limelight its chief executive officer, Vinita Gupta. The elder daughter of Lupin founder-chairman Desh Bandhu Gupta, Vinita is among a handful of female entrepreneurs calling the shots in the Indian pharma and healthcare space, predominantly controlled by men. A pharmacy graduate from the University of Mumbai and an MBA from J L Kellog Graduate School of Management, the 47-year-old is today one of the most important people in the US pharma space at present, say industry experts dna spoke to. Vinita also found place in Forbes' 2014 list of 50 'Power Businesswomen' in Asia.

Maryland-based Vinita, who took charge of the US business in 1992, plays a significant role when it comes to taking tough calls, along with brother Nilesh Gupta, who became managing director in 2013. 

From the manufacturer of primarily anti-tuberculosis drugs to the third largest pharma company by sales and the second largest in terms of market capitalisation, Lupin has come a long way under DB Gupta and former managing director and present vice-chairman Kamal Sharma. The brother-sister duo of Nilesh and Vinita played a critical role to make the company what it is today. From a total income of Rs 2,912.82 crore in 2007-08, Lupin has taken long strides to Rs 13,009.76 crore in 2014-15. Net profit grew from Rs 408.25 crore in 2007-08 to Rs 2,403.24 crore in 2014-15. This is largely driven by the US sales, which contributes to nearly 40% of the company’s overall business.

Lupin today is the fifth largest generic player in the US (with 5.3% market share by prescriptions as per IMS Health) and with this deal the company hopes to strengthen its US portfolio. The recent acquisition offers Lupin its first manufacturing base in the US along with a pipeline of strong 66 products awaiting the US FDA approvals, largely in dermatology, controlled substances and other high-value niche generics.

Vinita, who lives with her husband Brij Sharma, a US-based entrepreneur, and son, has a dream: to take her company's revenues to $5 billion by 2018.

Source: http://www.dnaindia.com/money/report-architect-of-lupin-s-rs-5600-cr-deal-is-indian-star-in-us-pharma-space-2110509

Comments

Popular posts from this blog

China-India joint summit discusses bilateral trade to improve pharma industry

PHYTOCON 2018 - Commercialization of medicinal plant products: Lab techniques to trade_14 April 2018